Last reviewed · How we verify
Measles vaccine
The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease.
The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease. Used for Prevention of measles in children and adults.
At a glance
| Generic name | Measles vaccine |
|---|---|
| Also known as | Measles vaccine (MeasBio) 0.5 mL, MeasBio® |
| Sponsor | Bandim Health Project |
| Drug class | Live attenuated vaccine |
| Target | Measles virus surface glycoproteins (H and F proteins) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live attenuated (weakened) measles virus that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly eliminate wild-type measles virus upon exposure, providing long-lasting protection against measles infection.
Approved indications
- Prevention of measles in children and adults
Common side effects
- Fever
- Rash
- Local injection site reactions (pain, erythema, swelling)
- Mild thrombocytopenia
Key clinical trials
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (PHASE2)
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE2)
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis (NA)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension (PHASE3)
- Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles vaccine CI brief — competitive landscape report
- Measles vaccine updates RSS · CI watch RSS
- Bandim Health Project portfolio CI